by Richard Daverman, PhD
April 1, 2013 -- Sanofi SA is actively seeking China M&A opportunities in the consumer healthcare and veterinary products sectors, according to the company’s CEO, Christopher Viehbacher, who was quoted in a Wall Street Journal article. The French big pharma wants to produce double-digit revenue growth in China during each of the next five years. Its China revenues were $1.3 billion last year, a 15% increase over the previous year. More details....
Stock Symbol: (NYSE: SNY)
